Facebook Twitter Tumblr Close Skip to main content
A Project of The Annenberg Public Policy Center

Q&A On Paxlovid, Pfizer’s COVID-19 Oral Antiviral

Q&A On Paxlovid, Pfizer’s COVID-19 Oral Antiviral

Once scarce, Paxlovid, an antiviral pill that is the preferred treatment for non-hospitalized high-risk COVID-19 patients, is no longer in such short supply. Here, we explain what the drug does, how well it works and what questions remain.

Q&A on Second COVID-19 Boosters for Older People

Q&A on Second COVID-19 Boosters for Older People

At the end of March, the Food and Drug Administration authorized a second COVID-19 booster dose for people 50 years of age and older. But the data supporting the extra shot is limited. Here, we break down the available evidence and share what scientists recommend.

Q&A on At-Home Rapid Tests

Q&A on At-Home Rapid Tests

The demand for at-home, rapid COVID-19 tests — sparked by the fast-spreading omicron variant in December — has continued in 2022. With that demand have come questions about the tests’ efficacy, how to use them and where to get them. We answer those queries and more.

Early Data on Omicron

Early Data on Omicron

As many Americans and others around the globe prepare for holiday travel and get-togethers, the omicron variant continues to be a concern. While the available data on transmission, vaccine effectiveness and severity of disease are still preliminary, here’s what we’ve learned so far.

Q&A on the Omicron Variant

Q&A on the Omicron Variant

On Nov. 24, South Africa told the World Health Organization that amid a recent increase in COVID-19 cases, it had identified a new variant — later named omicron — with a high number of mutations, raising concerns that it could spread more easily than other variants of the coronavirus. We’ll go through what we know so far about omicron.

A Guide to Pfizer/BioNTech’s Pediatric COVID-19 Vaccine for Kids 5-11

A Guide to Pfizer/BioNTech’s Pediatric COVID-19 Vaccine for Kids 5-11

As with its adult vaccine, Pfizer/BioNTech was the first to cross the finish line and offer a Food and Drug Administration-authorized COVID-19 vaccine to children ages 5 through 11. Here, we describe how it’s different from its grown-up cousin and what experts are saying about who should get it.

Biden’s Controversial COVID-19 Vaccine Booster Plan

Biden’s Controversial COVID-19 Vaccine Booster Plan

The Biden administration announced that third shots of the two mRNA COVID-19 vaccines would be available to healthy people starting in mid-September. But many scientists say it’s not yet clear that boosters are needed.

The Facts – and Gaps – on the Origin of the Coronavirus

The Facts – and Gaps – on the Origin of the Coronavirus

Despite increased media attention to the possibility that the novel coronavirus may have escaped from a lab, no credible evidence has emerged to support it and most scientists think the virus likely has a natural origin.